Carolyn J. Loveridge
Glasgow, SCT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer.
Journal: BJU international
Published: July 18, 2022
Evaluation of the Suitability of RNAscope as a Technique to Measure Gene Expression in Clinical Diagnostics: A Systematic Review.
Journal: Molecular diagnosis & therapy
Published: December 02, 2021
Correction: BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
Journal: Oncogene
Published: December 21, 2019
BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
Journal: Oncogene
Published: June 21, 2019
Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.
Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.
Journal: EMBO molecular medicine
Published: March 16, 2018
Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity.
Journal: Scientific reports
Published: February 14, 2017
Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 01, 2016
p300-mediated acetylation of COMMD1 regulates its stability, and the ubiquitylation and nucleolar translocation of the RelA NF-κB subunit.
Journal: Journal of cell science
Published: July 31, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026